×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
📊
Experiments
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
Vision
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
Vision
Showcase
Demo
←
Home
/
Wiki
/
Disease: Investment Landscape: Parkinson's Disease
disease
746 words
KG: ent-dise-42612378
2026-03-25
kind:disease
section:diseases
state:published
Contents
Investment Landscape: Parkinson's Disease
Disease Info
PHASE1
337
PHASE1, PHASE2
108
PHASE2
485
PHASE2, PHASE3
54
PHASE3
253
PHASE4
184
NA
2006
Not Applicable
1128
RECRUITING
684
ACTIVE_NOT_RECRUITING
148
NOT_YET_RECRUITING
229
COMPLETED
2369
Databases
OMIM
Orphanet
ClinicalTrials
PubMed
Knowledge Graph
Related Hypotheses (10)
Purinergic Signaling Polarization Control
Score: 0.55
Mechanosensitive Ion Channel Reprogramming
Score: 0.51
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46
TREM2-Dependent Microglial Senescence Transition
Score: 0.74
Microbial Inflammasome Priming Prevention
Score: 0.58
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
TREM2-mediated microglial tau clearance enhancement
Score: 0.49
APOE-TREM2 Interaction Modulation
Score: 0.48
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.43
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.41
Show 5 more
Related Analyses (18)
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Show 13 more
Related Experiments (30)
Down Syndrome Alzheimer's Disease: Mechanisms and Therapeuti
clinical · proposed · Score: 0.40
Spinocerebellar Ataxia (SCA) Disease-Modifying Therapy Devel
validation · proposed · Score: 0.40
Longitudinal TLR2 reporter gene study in α-synuclein mice
validation · proposed · Score: 0.90
iPSC-derived astrocyte-neuron co-culture mitochondrial trans
exploratory · proposed · Score: 0.90
TLR expression analysis in Parkinson's disease patients
clinical · proposed · Score: 0.85
Dexamethasone treatment study in α-synuclein mice
validation · proposed · Score: 0.85
TLR expression in α-synuclein overexpressing mice
validation · proposed · Score: 0.80
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40
Show 25 more
See Also (15)
Yoga Therapy for Neurodegeneration
therapeutic · Pages share 3 hypotheses
YAP/TEAD Pathway Modulators for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Wnt Signaling Modulators for Neurodegeneration
therapeutic · Pages share 3 hypotheses
vitamin-d-therapy-neurodegeneration
therapeutic · Pages share 3 hypotheses
Vitamin B Complex Therapy for Neurodegeneration
therapeutic · Pages share 3 hypotheses
VIP/VPAC Receptor Modulators for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Vestibular and Balance Therapy for CBS/PSP
therapeutic · Pages share 3 hypotheses
VEGF and Angiogenesis Therapy
therapeutic · Pages share 3 hypotheses
Urolithin A for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Urolithin A for Neurodegeneration
therapeutic · Pages share 3 hypotheses
tudca-udca-neurodegeneration
therapeutic · Pages share 3 hypotheses
TRPM8 Agonists for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Triple Incretin Agonists (GLP-1/GIP/Glucagon) for Neuro
therapeutic · Pages share 3 hypotheses
TREM2 Agonist Therapy for Neurodegeneration
therapeutic · Pages share 3 hypotheses
Transcutaneous Vagal Nerve Stimulation (tVNS) for Parki
therapeutic · Pages share 3 hypotheses
Show 10 more